6533b836fe1ef96bd12a12f8
RESEARCH PRODUCT
“Are There New Chemotherapy Drugs Behind the Corner?”
Marisol HuertaNoelia TarazonaAndrés CervantesValentina Gambardellasubject
Oncologymedicine.medical_specialtyBevacizumabbusiness.industryColorectal cancermedicine.medical_treatmentmedicine.diseaseRamucirumabOxaliplatinIrinotecanchemistry.chemical_compoundchemistryInternal medicineRegorafenibmedicinebusinessAdjuvantmedicine.drugAfliberceptdescription
Up to now, the backbone of both adjuvant and palliative chemotherapy for colorectal cancer is still represented by 5-fluorouracil (5FU). However, we have currently several approved drugs with significant clinical activity in metastatic colon cancer. Apart from cytotoxics such as oxaliplatin, irinotecan, and fluoropyrimidines, we have antiangiogenics (bevacizumab, aflibercept, and ramucirumab), anti-epidermal growth factor receptor (EGFR), and tyrosine kinase inhibitors such as regorafenib. Despite remarkable prolongation of median survival, exceeding 24 months, most patients will be progressing over different lines of therapy, and there is a need and a role for new compounds to be added to our therapeutic armamentarium to improve efficacy [1].
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-01-01 |